Gastrin I (human): Unlocking CCK2 Signaling in Intestinal Organoids

Introduction

Understanding the intricate mechanisms of gastric acid secretion and gastrointestinal (GI) physiology is pivotal for advancing drug discovery, disease modeling, and translational medicine. Gastrin I (human) (SKU: B5358), an endogenous regulatory peptide, serves as a potent gastric acid secretion regulator and CCK2 receptor agonist. While previous literature has highlighted its role in traditional in vitro models and organoid platforms, this article delves deeper—focusing on the molecular and cellular implications of Gastrin I-driven CCK2 receptor signaling within hiPSC-derived intestinal organoids, and its transformative impact on next-generation pharmacokinetic and GI disorder research. Uniquely, we synthesize the latest protocols in stem cell-derived organoid technology with the precision of APExBIO’s high-purity Gastrin I, bridging a critical gap in experimental reproducibility and mechanistic insight.

Gastrin I (human): Molecular Identity and Biochemical Properties

Gastrin I (human) is a 17-amino acid peptide with a molecular weight of 2098.22 Da and CAS number 10047-33-3. Synthesized as a white lyophilized solid and supplied by APExBIO, it is characterized by exceptional purity (≥98% by HPLC and MS) and is insoluble in water and ethanol but readily soluble in DMSO at concentrations ≥21 mg/mL. For optimal stability, it should be stored desiccated at -20°C and used promptly after reconstitution, as solutions are not recommended for long-term storage. These biochemical characteristics ensure consistent performance in demanding in vitro applications, from cell monolayers to complex 3D organoid systems.

Mechanism of Action: Gastrin I as a CCK2 Receptor Agonist

Receptor-Mediated Signal Transduction

At the heart of Gastrin I’s physiological action lies its selective activation of the cholecystokinin B (CCK2) receptor, a G-protein-coupled receptor (GPCR) predominantly expressed on gastric parietal cells and various cell types in the GI tract. Upon binding, Gastrin I initiates a cascade of intracellular signaling events, notably the phospholipase C (PLC) pathway, which elevates intracellular calcium levels and activates protein kinase C (PKC). This, in turn, triggers the activation of H⁺/K⁺-ATPase proton pumps, culminating in increased gastric acid secretion. This tightly regulated process underpins both normal GI physiology and the pathogenesis of disorders such as Zollinger-Ellison syndrome and peptic ulcer disease.

Experimental Dissection of CCK2 Signaling

The high specificity and stability of Gastrin I (human) make it an invaluable tool for gastric acid secretion pathway research and receptor-mediated signal transduction studies. Researchers utilize this peptide in both traditional monolayer cultures and, increasingly, in advanced organoid systems to dissect the temporal dynamics, dose-responsiveness, and downstream transcriptional effects of CCK2 receptor signaling. These applications are especially relevant in pharmacological screening, where precise modulation of proton pump activation is essential for evaluating candidate therapeutics targeting gastric acidity.

hiPSC-Derived Intestinal Organoids: A Paradigm Shift in GI Research

Limitations of Conventional Models

Historically, GI physiology studies have relied on animal models (e.g., rodents) and cancer-derived cell lines such as Caco-2. However, these systems suffer from significant limitations—species-specific differences in gene expression, notably in cytochrome P450 (CYP) enzymes, and aberrant cellular phenotypes, restricting their predictive power for human pharmacokinetics and pathophysiology. The need for more physiologically relevant, customizable platforms has driven the rise of stem cell-derived organoids.

Advances in Intestinal Organoid Technology

Recent breakthroughs, as detailed in the seminal study by Saito et al. (European Journal of Cell Biology, 2025), have established protocols for generating intestinal organoids (IOs) directly from human induced pluripotent stem cells (hiPSCs). These hiPSC-IOs can be propagated long-term, differentiated into mature enterocyte-rich monolayers, and cryopreserved for consistent use. Importantly, they recapitulate key features of the human intestinal epithelium, including functional CYP3A4 expression and transporter activities—attributes critical for accurate drug metabolism and absorption studies.

Integrating Gastrin I (human) with hiPSC-Derived Organoids: Experimental Opportunities

Elucidating CCK2 Receptor Signaling in a Human Context

By introducing Gastrin I (human) into hiPSC-derived intestinal organoid cultures, researchers can precisely activate CCK2 receptor signaling within a genetically human, multicellular microenvironment. This integration enables:

• Dynamic Profiling of Gastric Acid Secretion Pathways: Quantifying acid production, proton pump activation, and downstream gene expression in response to controlled Gastrin I stimulation.
• Dissection of Receptor-Mediated Signal Transduction: Using advanced imaging, calcium flux assays, and phosphoproteomic analyses to map the temporal and spatial dynamics of CCK2 signaling networks.
• Modeling GI Disorders and Therapeutic Interventions: Mimicking hypergastrinemia, acid hypersecretion, or receptor antagonism scenarios to evaluate candidate drug effects or disease mechanisms.

Advantages Over Prior Approaches

Unlike traditional Caco-2 or animal-based models, the hiPSC-IO + Gastrin I system offers:

• Human-specific expression of key metabolic enzymes and receptors.
• 3D tissue architecture and multicellular complexity, including enteroendocrine cells responsive to peptide hormones.
• Customizability for patient-derived or genetically engineered lines to model rare or complex GI pathologies.

This synergy unlocks unparalleled opportunities for dissecting the interplay between CCK2 receptor signaling, proton pump activation, and GI epithelial homeostasis, as discussed in the referenced organoid study (Saito et al., 2025).

Comparative Analysis: Building Upon and Differentiating from Existing Literature

Several recent articles have explored the application of Gastrin I (human) in GI research, with each offering distinct perspectives:

• "Gastrin I (human): A Molecular Gateway to Advanced GI Physiology" provides an insightful overview of Gastrin I integration with hiPSC-derived organoids, focusing on translational pharmacokinetics. Our article builds upon this by systematically deconstructing the molecular mechanisms of CCK2 receptor signaling and emphasizing experimental design for receptor-mediated pathway analysis.
• "Gastrin I (human): Driving Innovation in High-Definition..." investigates Gastrin I’s mechanistic role in advanced organoid platforms. In contrast, our discussion prioritizes the integration of high-purity, rigorously characterized APExBIO Gastrin I into stem cell-derived organoids, highlighting reproducibility and experimental precision.
• While "Gastrin I (human): A Precision Tool for Dissecting Gastric Acid Secretion Pathways" delves into mechanistic in vitro models, our approach extends these insights by proposing advanced multi-parametric analyses (e.g., phosphoproteomics, single-cell signaling) uniquely enabled by organoid systems.

Applications in Gastrointestinal Disorder Research and Drug Discovery

Modeling GI Disease States

Diseases such as atrophic gastritis, peptic ulcers, and certain neuroendocrine tumors are characterized by dysregulated Gastrin I/CCK2 receptor signaling. Using hiPSC-derived organoids treated with Gastrin I (human), researchers can model these pathological states in vitro, enabling:

• Investigation of disease-specific CCK2 receptor mutations or expression patterns.
• Screening of proton pump inhibitors and CCK2 antagonists for efficacy and off-target effects.
• Personalized medicine approaches using patient-derived hiPSCs to recapitulate individual disease phenotypes.

Pharmacokinetic and Pharmacodynamic Studies

As highlighted in the core reference (Saito et al., 2025), hiPSC-IOs provide a robust platform for pharmacokinetic studies, surpassing traditional models in predictive accuracy for human drug absorption and metabolism. The addition of Gastrin I (human) enables precise modulation of gastric acid secretion, which directly impacts the solubility, absorption, and bioavailability of orally administered drugs. This facilitates:

• Quantitative assessment of drug stability and metabolic transformation under physiologically relevant acidic conditions.
• Evaluation of transporter-mediated drug efflux and CYP450 enzyme activity in the presence of physiologically appropriate hormone levels.

Technical Considerations and Best Practices

To maximize reproducibility and data quality in organoid-based gastric acid secretion regulator studies:

• Utilize high-purity Gastrin I (human) from APExBIO to minimize batch-to-batch variability.
• Prepare peptide solutions freshly in DMSO at recommended concentrations (≥21 mg/mL), avoiding prolonged storage.
• Standardize organoid culture protocols, including Matrigel composition and growth factor supplementation, to maintain consistent baseline CCK2 receptor expression.
• Employ multi-parametric readouts—such as live-cell imaging, pH-sensitive dyes, and transcriptomic profiling—to capture the full spectrum of Gastrin I-induced responses.

Conclusion and Future Outlook

The integration of Gastrin I (human) with hiPSC-derived intestinal organoids marks a paradigm shift in gastrointestinal physiology studies, gastric acid secretion pathway research, and GI disorder modeling. By enabling precise, human-relevant interrogation of CCK2 receptor signaling and proton pump activation, this approach transcends the limitations of legacy models, paving the way for next-generation pharmacokinetic screens, personalized medicine, and high-resolution disease modeling. As organoid technologies continue to evolve—incorporating co-cultures, microfluidics, and single-cell multiomics—the strategic use of rigorously characterized peptides from APExBIO will remain central to advancing the frontiers of GI research and therapeutic innovation.